RESUMO
PURPOSE: To investigate the dose rate dependence of MapCHECK3 and its influence on measurement accuracy, as well as the effect of dose rate correction. MATERIALS AND METHODS: The average and instantaneous dose rate dependence of MapCHECK2 and MapCHECK3 were studied. The accuracy of measurements was investigated where the dose rate differed significantly between dose calibration of the MapCHECK and the measurement. Measurements investigated include: the central axis dose for different fields at different depths, off-axis doses outside the field, and off-axis doses along the wedge direction. Measurements using an ion chamber were taken as the reference. Exponential functions were fit to account for average and instantaneous dose rate dependence for MapCHECK3 and used for dose rate correction. The effect of the dose rate correction was studied by comparing the differences between the measurements for MapCHECK (with and without the correction) and the reference. RESULTS: The maximum dose rate dependence of MapCHECK3 is greater than 2.5%. If the dose calibration factor derived from a 10 × 10 cm2 open field at 10 cm depth was used for measurements, the average differences in central diode dose were 0.8% ± 1.0% and 1.0% ± 0.8% for the studied field sizes and measurement depths, respectively. The introduction of wedge would not only induce -1.8% ± 1.3% difference in central diode dose, but also overestimate the effective wedge angle. After the instantaneous dose rate correction, above differences can be changed to 1.9% ± 8.1%, 0.2% ± 0.1%, and 0.0% ± 0.9%. The pass rate can be improved from 98.4% to 98.8%, 98.3%-100.0%, and 96.3%-100.0%, respectively. CONCLUSION: Compared with MapCHECK2 (SunPoint1 diodes), the more pronounced dose rate dependence of MapCHECK3 (SunPoint2 diodes) should be carefully considered. To ensure highly accurate measurement, it is suggested to perform the dose calibration at the same condition where measurement will be performed. Otherwise, the dose rate correction should be applied.
RESUMO
PURPOSE: To evaluate the dosimetric characteristics of ZAP-X stereotactic radiosurgery (SRS) for single brain metastasis by comparing with two mature SRS platforms. METHODS: Thirteen patients with single brain metastasis treated with CyberKnife (CK) G4 were selected retrospectively. The prescription dose for the planning target volume (PTV) was 18-24 Gy for 1-3 fractions. The PTV volume ranged from 0.44 to 11.52 cc.Treatment plans of thirteen patients were replanned using the ZAP-X plan system and the Gamma Knife (GK) ICON plan system with the same prescription dose and organs at risk (OARs) constraints. The prescription dose of PTV was normalized to 70% for both ZAP-X and CK, while it was 50% for GK. The dosimetric parameters of three groups included the plan characteristics (CI, GI, GSI, beams, MUs, treatment time), PTV (D2, D95, D98, Dmin, Dmean, Coverage), brain tissue (volume of 100%-10% prescription dose irradiation V100%-V10%, Dmean) and other OARs (Dmax, Dmean),all of these were compared and evaluated. All data were read and analyzed with MIM Maestro. One-way ANOVA or a multisample Friedman rank sum test was performed, where p < 0.05 indicated significant differences. RESULTS: The CI of GK was significantly lower than that of ZAP-X and CK. Regarding the mean value, ZAP-X had a lower GI and higher GSI, but there was no significant difference among the three groups. The MUs of ZAP-X were significantly lower than those of CK, and the mean value of the treatment time of ZAP-X was significantly shorter than that of CK. For PTV, the D95, D98, and target coverage of CK were higher, while the mean of Dmin of GK was significantly lower than that of CK and ZAP-X. For brain tissue, ZAP-X showed a smaller volume from V100% to V20%; the statistical results of V60% and V50% showed a difference between ZAP-X and GK, while the V40% and V30% showed a significant difference between ZAP-X and the other two groups; V10% and Dmean indicated that GK was better. Excluding the Dmax of the brainstem, right optic nerve and optic chiasm, the mean value of all other OARs was less than 1 Gy. For the brainstem, GK and ZAP-X had better protection, especially at the maximum dose. CONCLUSION: For the SRS treating single brain metastasis, all three treatment devices, ZAP-X system, CyberKnife G4 system, and GammaKnife system, could meet clinical treatment requirements. The newly platform ZAP-X could provide a high-quality plan equivalent to or even better than CyberKnife and Gamma Knife, with ZAP-X presenting a certain dose advantage, especially with a more conformal dose distribution and better protection for brain tissue. As the ZAP-X systems get continuous improvements and upgrades, they may become a new SRS platform for the treatment of brain metastasis.
Assuntos
Neoplasias Encefálicas , Radiocirurgia , Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador , Humanos , Radiocirurgia/métodos , Neoplasias Encefálicas/secundário , Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/cirurgia , Masculino , Planejamento da Radioterapia Assistida por Computador/métodos , Estudos Retrospectivos , Feminino , Pessoa de Meia-Idade , Radiometria , Idoso , Adulto , Órgãos em Risco/efeitos da radiaçãoRESUMO
The inference of cell-cell communication (CCC) is crucial for a better understanding of complex cellular dynamics and regulatory mechanisms in biological systems. However, accurately inferring spatial CCCs at single-cell resolution remains a significant challenge. To address this issue, we present a versatile method, called DeepTalk, to infer spatial CCC at single-cell resolution by integrating single-cell RNA sequencing (scRNA-seq) data and spatial transcriptomics (ST) data. DeepTalk utilizes graph attention network (GAT) to integrate scRNA-seq and ST data, which enables accurate cell-type identification for single-cell ST data and deconvolution for spot-based ST data. Then, DeepTalk can capture the connections among cells at multiple levels using subgraph-based GAT, and further achieve spatially resolved CCC inference at single-cell resolution. DeepTalk achieves excellent performance in discovering meaningful spatial CCCs on multiple cross-platform datasets, which demonstrates its superior ability to dissect cellular behavior within intricate biological processes.
Assuntos
Comunicação Celular , Análise de Célula Única , Transcriptoma , Análise de Célula Única/métodos , Humanos , Perfilação da Expressão Gênica/métodos , Análise de Sequência de RNA/métodos , Animais , Algoritmos , Biologia Computacional/métodosRESUMO
Gamma Knife radiosurgery (GKRS) is a well-established technique in radiation therapy (RT) for treating small-size brain tumors. It administers highly concentrated doses during each treatment fraction, with even minor dose errors posing a significant risk of causing severe damage to healthy tissues. It underscores the critical need for precise and meticulous precision in GKRS. However, the planning process for GKRS is complex and time-consuming, heavily reliant on the expertise of medical physicists. Incorporating deep learning approaches for GKRS dose prediction can reduce this dependency, improve planning efficiency and homogeneity, streamline clinical workflows, and reduce patient lagging times. Despite this, precise Gamma Knife plan dose distribution prediction using existing models remains a significant challenge. The complexity stems from the intricate nature of dose distributions, subtle contrasts in CT scans, and the interdependence of dosimetric metrics. To overcome these challenges, we have developed a "Cascaded-Deep-Supervised" Convolutional Neural Network (CDS-CNN) that employs a hybrid-weighted optimization scheme. Our innovative method incorporates multi-level deep supervision and a strategic sequential multi-network training approach. It enables the extraction of intra-slice and inter-slice features, leading to more realistic dose predictions with additional contextual information. CDS-CNN was trained and evaluated using data from 105 brain cancer patients who underwent GKRS treatment, with 85 cases used for training and 20 for testing. Quantitative assessments and statistical analyses demonstrated high consistency between the predicted dose distributions and the reference doses from the treatment planning system (TPS). The 3D overall gamma passing rates (GPRs) reached 97.15% ± 1.36% (3 mm/3%, 10% threshold), surpassing the previous best performance by 2.53% using the 3D Dense U-Net model. When evaluated against more stringent criteria (2 mm/3%, 10% threshold, and 1 mm/3%, 10% threshold), the overall GPRs still achieved 96.53% ± 1.08% and 95.03% ± 1.18%. Furthermore, the average target coverage (TC) was 98.33% ± 1.16%, dose selectivity (DS) was 0.57 ± 0.10, gradient index (GI) was 2.69 ± 0.30, and homogeneity index (HI) was 1.79 ± 0.09. Compared to the 3D Dense U-Net, CDS-CNN predictions demonstrated a 3.5% improvement in TC, and CDS-CNN's dose prediction yielded better outcomes than the 3D Dense U-Net across all evaluation criteria. The experimental results demonstrated that the proposed CDS-CNN model outperformed other models in predicting GKRS dose distributions, with predictions closely matching the TPS doses.
RESUMO
Objective.In this work, we aim to propose an accurate and robust spectrum estimation method by synergistically combining x-ray imaging physics with a convolutional neural network (CNN).Approach.The approach relies on transmission measurements, and the estimated spectrum is formulated as a convolutional summation of a few model spectra generated using Monte Carlo simulation. The difference between the actual and estimated projections is utilized as the loss function to train the network. We contrasted this approach with the weighted sums of model spectra approach previously proposed. Comprehensive studies were performed to demonstrate the robustness and accuracy of the proposed approach in various scenarios.Main results.The results show the desirable accuracy of the CNN-based method for spectrum estimation. The ME and NRMSE were -0.021 keV and 3.04% for 80 kVp, and 0.006 keV and 4.44% for 100 kVp, superior to the previous approach. The robustness test and experimental study also demonstrated superior performances. The CNN-based approach yielded remarkably consistent results in phantoms with various material combinations, and the CNN-based approach was robust concerning spectrum generators and calibration phantoms.Significance. We proposed a method for estimating the real spectrum by integrating a deep learning model with real imaging physics. The results demonstrated that this method was accurate and robust in estimating the spectrum, and it is potentially helpful for broad x-ray imaging tasks.
Assuntos
Método de Monte Carlo , Redes Neurais de Computação , Imagens de Fantasmas , Raios X , Processamento de Imagem Assistida por Computador/métodosRESUMO
T cells recognize tumor antigens and initiate an anticancer immune response in the very early stages of tumor development, and the antigen specificity of T cells is determined by the T-cell receptor (TCR). Therefore, monitoring changes in the TCR repertoire in peripheral blood may offer a strategy to detect various cancers at a relatively early stage. Here, we developed the deep learning framework iCanTCR to identify patients with cancer based on the TCR repertoire. The iCanTCR framework uses TCRß sequences from an individual as an input and outputs the predicted cancer probability. The model was trained on over 2,000 publicly available TCR repertoires from 11 types of cancer and healthy controls. Analysis of several additional publicly available datasets validated the ability of iCanTCR to distinguish patients with cancer from noncancer individuals and demonstrated the capability of iCanTCR for the accurate classification of multiple cancers. Importantly, iCanTCR precisely identified individuals with early-stage cancer with an AUC of 86%. Altogether, this work provides a liquid biopsy approach to capture immune signals from peripheral blood for noninvasive cancer diagnosis. SIGNIFICANCE: Development of a deep learning-based method for multicancer detection using the TCR repertoire in the peripheral blood establishes the potential of evaluating circulating immune signals for noninvasive early cancer detection.
Assuntos
Aprendizado Profundo , Detecção Precoce de Câncer , Neoplasias , Receptores de Antígenos de Linfócitos T , Humanos , Neoplasias/imunologia , Neoplasias/sangue , Neoplasias/diagnóstico , Receptores de Antígenos de Linfócitos T/imunologia , Detecção Precoce de Câncer/métodos , Biomarcadores Tumorais/sangue , Biomarcadores Tumorais/imunologia , Linfócitos T/imunologia , Linfócitos T/metabolismoRESUMO
As the genome is organized into a three-dimensional structure in intracellular space, epigenomic information also has a complex spatial arrangement. However, most epigenetic studies describe locations of methylation marks, chromatin accessibility regions, and histone modifications in the horizontal dimension. Proper spatial epigenomic information has rarely been obtained. In this study, we designed spatial chromatin accessibility sequencing (SCA-seq) to resolve the genome conformation by capturing the epigenetic information in single-molecular resolution while simultaneously resolving the genome conformation. Using SCA-seq, we are able to examine the spatial interaction of chromatin accessibility (e.g. enhancer-promoter contacts), CpG island methylation, and spatial insulating functions of the CCCTC-binding factor. We demonstrate that SCA-seq paves the way to explore the mechanism of epigenetic interactions and extends our knowledge in 3D packaging of DNA in the nucleus.
Assuntos
Cromatina , Epigenômica , Cromatina/genética , Cromossomos , DNA , Sequências Reguladoras de Ácido Nucleico , Metilação de DNARESUMO
BACKGROUND: Due to inconsistent positioning, tumor shrinking, and weight loss during fractionated treatment, the initial plan was no longer appropriate after a few fractional treatments, and the patient will require adaptive helical tomotherapy (HT) to overcome the issue. Patients are scanned with megavoltage computed tomography (MVCT) before each fractional treatment, which is utilized for patient setup and provides information for dose reconstruction. However, the low contrast and high noise of MVCT make it challenging to delineate treatment targets and organs at risk (OAR). PURPOSE: This study developed a deep-learning-based approach to generate high-quality synthetic kilovoltage computed tomography (skVCT) from MVCT and meet clinical dose requirements. METHODS: Data from 41 head and neck cancer patients were collected; 25 (2995 slices) were used for training, and 16 (1898 slices) for testing. A cycle generative adversarial network (cycleGAN) based on attention gate and residual blocks was used to generate MVCT-based skVCT. For the 16 patients, kVCT-based plans were transferred to skVCT images and electron density profile-corrected MVCT images to recalculate the dose. The quantitative indices and clinically relevant dosimetric metrics, including the mean absolute error (MAE), structural similarity index measure (SSIM), peak signal-to-noise ratio (PSNR), gamma passing rates, and dose-volume-histogram (DVH) parameters (Dmax , Dmean , Dmin ), were used to assess the skVCT images. RESULTS: The MAE, PSNR, and SSIM of MVCT were 109.6 ± 12.3 HU, 27.5 ± 1.1 dB, and 91.9% ± 1.7%, respectively, while those of skVCT were 60.6 ± 9.0 HU, 34.0 ± 1.9 dB, and 96.5% ± 1.1%. The image quality and contrast were enhanced, and the noise was reduced. The gamma passing rates improved from 98.31% ± 1.11% to 99.71% ± 0.20% (2 mm/2%) and 99.77% ± 0.18% to 99.98% ± 0.02% (3 mm/3%). No significant differences (p > 0.05) were observed in DVH parameters between kVCT and skVCT. CONCLUSION: With training on a small data set (2995 slices), the model successfully generated skVCT with improved image quality, and the dose calculation accuracy was similar to that of MVCT. MVCT-based skVCT can increase treatment accuracy and offer the possibility of implementing adaptive radiotherapy.
Assuntos
Neoplasias de Cabeça e Pescoço , Radioterapia Conformacional , Humanos , Radioterapia Conformacional/métodos , Neoplasias de Cabeça e Pescoço/diagnóstico por imagem , Neoplasias de Cabeça e Pescoço/radioterapia , Planejamento da Radioterapia Assistida por Computador/métodos , Dosagem Radioterapêutica , Tomografia Computadorizada de Feixe Cônico , Processamento de Imagem Assistida por ComputadorRESUMO
Cancer progression is a dynamic process of continuous evolution, in which genetic diversity and heterogeneity are generated by clonal and subclonal amplification based on random mutations. Traditional cancer treatment strategies have a great challenge, which often leads to treatment failure due to drug resistance. Integrating evolutionary dynamics into treatment regimens may be an effective way to overcome the problem of drug resistance. In particular, a potential treatment is adaptive therapy, which strategy advocates containment strategies that adjust the treatment cycles according to tumor evolution to control the growth of treatment-resistant cells. In this review, we first summarize the shortcomings of traditional tumor treatment methods in evolution and then introduce the theoretical basis and research status of adaptive therapy. By analyzing the limitations of adaptive therapy and exploring possible solutions, we can broaden people's understanding of adaptive therapy and provide new insights and strategies for tumor treatment.
Assuntos
Resistencia a Medicamentos Antineoplásicos , Neoplasias , Humanos , Resistencia a Medicamentos Antineoplásicos/genética , Neoplasias/terapia , Neoplasias/tratamento farmacológico , Falha de TratamentoRESUMO
Chronic stress refers to continuous emotional changes and psychological pressure that individuals experience when they are unable to adjust and stabilize the internal environment over an extended period. It can increase the pressure on endocrine mediators and cytokines in the circulation, as well as tissues throughout the hypothalamic-pituitary-adrenaline (HPA) axis and sympathetic nervous system (SNS); thus, evolving the internal environment of the tumor. This review assesses several key issues, involving psychosocial factors, and integrates clinical, cellular, and molecular studies-as well as the latest research progress-to provide a mechanistic understanding regarding breast oncopsychology. We propose that chronic stress contributes to large individual diferences in the prognosis of breast cancer survivors because they change the basic physiological processes of the endocrine and immune systems, which in turn regulate tumor growth. The study of psychological and physiological reactions of breast cancer patients suggests a new idea for psychological intervention and clinical treatment for breast cancer patients.
RESUMO
Objective. Proton source model commissioning (PSMC) is critical for ensuring accurate dose calculation in pencil beam scanning (PBS) proton therapy using Monte Carlo (MC) simulations. PSMC aims to match the calculated dose to the delivered dose. However, commissioning the 'nominal energy' and 'energy spread' parameters in PSMC can be challenging, as these parameters cannot be directly obtained from solving equations. To efficiently and accurately commission the nominal energy and energy spread in a proton source model, we developed a convolution neural network (CNN) named 'PSMC-Net.'Methods. The PSMC-Net was trained separately for 33 energies (E, 70-225 MeV with a step of 5 MeV plus 226.09 MeV). For eachE, a dataset was generated consisting of 150 source model parameters (15 nominal energies ∈ [E,E+ 1.5 MeV], ten spreads ∈ [0, 1]) and the corresponding 150 MC integrated depth doses (IDDs). Of these 150 data pairs, 130 were used for training the network, 10 for validation, and 10 for testing.Results. The source model, built by 33 measured IDDs and 33 PSMC-Nets (cost 0.01 s), was used to compute the MC IDDs. The gamma passing rate (GPRs, 1 mm/1%) between MC and measured IDDs was 99.91 ± 0.12%. However, when no commissioning was made, the corresponding GPR was reduced to 54.11 ± 22.36%, highlighting the tremendous significance of our CNN commissioning method. Furthermore, the MC doses of a spread-out Bragg peak and 20 patient PBS plans were also calculated, and average 3D GPRs (2 mm/2% with a 10% threshold) were 99.89% and 99.96 ± 0.06%, respectively.Significance. We proposed a nova commissioning method of the proton source model using CNNs, which made the PSMC process easy, efficient, and accurate.
Assuntos
Terapia com Prótons , Humanos , Terapia com Prótons/métodos , Prótons , Dosagem Radioterapêutica , Imagens de Fantasmas , Redes Neurais de Computação , Planejamento da Radioterapia Assistida por Computador , Método de Monte CarloRESUMO
BACKGROUND: Early detection is critical for improving the survival of breast cancer (BC) patients. Exhaled breath testing as a non-invasive technique might help to improve BC detection. However, the breath test accuracy for BC diagnosis is unclear. METHODS: This multi-center cohort study consecutively recruited 5047 women from four areas of China who underwent BC screening. Breath samples were collected through standardized breath collection procedures. Volatile organic compound (VOC) markers were identified from a high-throughput breathomics analysis by the high-pressure photon ionization-time-of-flight mass spectrometry (HPPI-TOFMS). Diagnostic models were constructed using the random forest algorithm in the discovery cohort and tested in three external validation cohorts. RESULTS: A total of 465 (9.21%) participants were identified with BC. Ten optimal VOC markers were identified to distinguish the breath samples of BC patients from those of non-cancer women. A diagnostic model (BreathBC) consisting of 10 optimal VOC markers showed an area under the curve (AUC) of 0.87 in external validation cohorts. BreathBC-Plus, which combined 10 VOC markers with risk factors, achieved better performance (AUC = 0.94 in the external validation cohorts), superior to that of mammography and ultrasound. Overall, the BreathBC-Plus detection rates were 96.97% for ductal carcinoma in situ, 85.06%, 90.00%, 88.24%, and 100% for stages I, II, III, and IV BC, respectively, with a specificity of 87.70% in the external validation cohorts. CONCLUSIONS: This is the largest study on breath tests to date. Considering the easy-to-perform procedure and high accuracy, these findings exemplify the potential applicability of breath tests in BC screening.
Assuntos
Neoplasias da Mama , Compostos Orgânicos Voláteis , Humanos , Feminino , Neoplasias da Mama/diagnóstico , Compostos Orgânicos Voláteis/análise , Estudos de Coortes , Detecção Precoce de Câncer/métodos , Testes Respiratórios/métodos , BiópsiaRESUMO
PURPOSE: We aimed to identify effectiveness-associated indicators and evaluate the optimal tumor reduction rate (TRR) after two cycles of neoadjuvant chemotherapy (NAC) in patients with invasive breast cancer. METHODS: This retrospective case-control study included patients who underwent at least four cycles of NAC at the Department of Breast Surgery between February 2013 and February 2020. A regression nomogram model for predicting pathological responses was constructed based on potential indicators. RESULTS: A total of 784 patients were included, of whom 170 (21.68%) reported pathological complete response (pCR) after NAC and 614 (78.32%) had residual invasive tumors. The clinical T stage, clinical N stage, molecular subtype, and TRR were identified as independent predictors of pCR. Patients with a TRR > 35% were more likely to achieve pCR (odds ratio, 5.396; 95% confidence interval [CI], 3.299-8.825). The receiver operating characteristic (ROC) curve was plotted using the probability value, and the area under the ROC curve was 0.892 (95% CI, 0.863-0.922). CONCLUSION: TRR > 35% is predictive of pCR after two cycles of NAC, and an early evaluation model using a nomogram based on five indicators, age, clinical T stage, clinical N stage, molecular subtype, and TRR, is applicable in patients with invasive breast cancer.
RESUMO
Neoadjuvant therapy (NAT) is currently recommended to patients with human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) that typically exhibit a poor prognosis. The tumor immune microenvironment profoundly affects the efficacy of NAT. However, the correlation between tumor-infiltrating lymphocytes or their specific subpopulations and the response to NAT in HER2+ BC remains largely unknown. In our study, the immune infiltration status of 295 patients was classified as "immune-rich" or "immune-poor" phenotypes. The "immune-rich" phenotype was significantly positively related to pathological complete response (pCR). Ten genes were correlated with both pCR and the immune phenotype based on the results of spline and logistic regression. We constructed a generalized non-linear model combining linear and non-linear gene effects and successfully validated its predictive power using an internal and external validation set (AUC = 0.819, 0.797; respectively) and a clinical set (accuracy = 0.75).
RESUMO
OBJECTIVE: Neoadjuvant therapy (NAT) has been widely implemented as an essential treatment to improve therapeutic efficacy in patients with locally-advanced cancer to reduce tumor burden and prolong survival, particularly for human epidermal growth receptor 2-positive and triple-negative breast cancer. The role of peripheral immune components in predicting therapeutic responses has received limited attention. Herein we determined the relationship between dynamic changes in peripheral immune indices and therapeutic responses during NAT administration. METHODS: Peripheral immune index data were collected from 134 patients before and after NAT. Logistic regression and machine learning algorithms were applied to the feature selection and model construction processes, respectively. RESULTS: Peripheral immune status with a greater number of CD3+ T cells before and after NAT, and a greater number of CD8+ T cells, fewer CD4+ T cells, and fewer NK cells after NAT was significantly related to a pathological complete response (P < 0.05). The post-NAT NK cell-to-pre-NAT NK cell ratio was negatively correlated with the response to NAT (HR = 0.13, P = 0.008). Based on the results of logistic regression, 14 reliable features (P < 0.05) were selected to construct the machine learning model. The random forest model exhibited the best power to predict efficacy of NAT among 10 machine learning model approaches (AUC = 0.733). CONCLUSIONS: Statistically significant relationships between several specific immune indices and the efficacy of NAT were revealed. A random forest model based on dynamic changes in peripheral immune indices showed robust performance in predicting NAT efficacy.
Assuntos
Terapia Neoadjuvante , Neoplasias de Mama Triplo Negativas , Humanos , Terapia Neoadjuvante/métodos , Linfócitos T CD8-Positivos , Neoplasias de Mama Triplo Negativas/tratamento farmacológico , Neoplasias de Mama Triplo Negativas/patologia , Aprendizado de Máquina , Células Matadoras NaturaisRESUMO
Although programmed death-ligand 1 (PD-L1) inhibitors have achieved some therapeutic success in breast cancer, their efficacy is limited by low therapeutic response rates, which is closely related to the immune escape of breast cancer cells. Tissue differentiation inducing non-protein coding RNA (TINCR), a long non-coding RNA, as an oncogenic gene associated with the progression of various malignant tumors, including breast cancer; however, the role of TINCR in tumor immunity, especially in breast cancer, remains unclear. We confirmed that TINCR upregulated PD-L1 expression in vivo and in vitro, and promoted the progression of breast cancer. Next, we revealed that TINCR knockdown can significantly improve the therapeutic effect of PD-L1 inhibitors in breast cancer in vivo. Mechanistically, TINCR recruits DNMT1 to promote the methylation of miR-199a-5p loci and inhibit its transcription. Furthermore, in the cytoplasm, TINCR potentially acts as a molecular sponge of miR-199a-5p and upregulates the stability of USP20 mRNA through a competing endogenous RNA (ceRNA) regulatory mechanism, thus promoting PD-L1 expression by decreasing its ubiquitination level. IFN-γ stimulation activates STAT1 by phosphorylation, which migrates into the nucleus to promote TINCR transcription. This is the first study to describe the regulatory role of TINCR in breast cancer tumor immunity, broadening the current paradigm of the functional diversity of TINCR in tumor biology. In addition, our study provides new research directions and potential therapeutic targets for PD-L1 inhibitors in breast cancer.
Assuntos
Neoplasias da Mama , MicroRNAs , RNA Longo não Codificante , Feminino , Humanos , Antígeno B7-H1/genética , Antígeno B7-H1/metabolismo , Neoplasias da Mama/genética , Neoplasias da Mama/terapia , Neoplasias da Mama/patologia , Linhagem Celular Tumoral , Proliferação de Células/genética , Regulação Neoplásica da Expressão Gênica , Inibidores de Checkpoint Imunológico , Imunoterapia , MicroRNAs/genética , MicroRNAs/metabolismo , RNA Longo não Codificante/genética , RNA Longo não Codificante/metabolismo , Fator de Transcrição STAT1/genética , Fator de Transcrição STAT1/metabolismo , Ubiquitina Tiolesterase/metabolismoRESUMO
Purpose: To investigate and compare 2 cone-beam computed tomography (CBCT) correction methods for CBCT-based dose calculation. Materials and Methods: Routine CBCT image sets of 12 head and neck cancer patients who received volumetric modulated arc therapy (VMAT) treatment were retrospectively analyzed. The CBCT images obtained using an on-board imager (OBI) at the first treatment fraction were firstly deformable registered and padded with the kVCT images to provide enough anatomical information about the tissues for dose calculation. Then, 2 CBCT correction methods were developed and applied to correct CBCT Hounsfield unit (HU) values. One method (HD method) is based on protocol-specific CBCT HU to physical density (HD) curve, and the other method (HM method) is based on histogram matching (HM) of HU value. The corrected CBCT images (CBCTHD and CBCTHM for HD and HM methods) were imported into the original planning system for dose calculation based on the HD curve of kVCT (the planning CT). The dose computation result was analyzed and discussed to compare these 2 CBCT-correction methods. Results: Dosimetric parameters, such as the Dmean, Dmax and D5% of the target volume in CBCT plan doses, were higher than those in the kVCT plan doses; however, the deviations were less than 2%. The D2%, in parallel organs such as the parotid glands, the deviations from the CBCTHM plan dose were less than those of the CBCTHD plan dose. The differences were statistically significant (P < .05). Meanwhile, the V30 value based on the HM method was better than that based on the HD method in the oral cavity region (P = .016). In addition, we also compared the γ passing rates of kVCT plan doses with the 2 CBCT plan doses, and negligible differences were found. Conclusion: The HM method was more suitable for head and neck cancer patients than the HD one. Furthermore, with the CBCTHM-based method, the dose calculation result better matches the kVCT-based dose calculation.
Assuntos
Neoplasias de Cabeça e Pescoço , Radioterapia de Intensidade Modulada , Humanos , Dosagem Radioterapêutica , Estudos Retrospectivos , Planejamento da Radioterapia Assistida por Computador/métodos , Imagens de Fantasmas , Neoplasias de Cabeça e Pescoço/diagnóstico por imagem , Neoplasias de Cabeça e Pescoço/radioterapia , Radioterapia de Intensidade Modulada/métodos , Tomografia Computadorizada de Feixe Cônico/métodos , Processamento de Imagem Assistida por Computador/métodosRESUMO
PURPOSE: During the radiation treatment planning process, one of the time-consuming procedures is the final high-resolution dose calculation, which obstacles the wide application of the emerging online adaptive radiotherapy techniques (OLART). There is an urgent desire for highly accurate and efficient dose calculation methods. This study aims to develop a dose super resolution-based deep learning model for fast and accurate dose prediction in clinical practice. METHOD: A Multi-stage Dose Super-Resolution Network (MDSR Net) architecture with sparse masks module and multi-stage progressive dose distribution restoration method were developed to predict high-resolution dose distribution using low-resolution data. A total of 340 VMAT plans from different disease sites were used, among which 240 randomly selected nasopharyngeal, lung, and cervix cases were used for model training, and the remaining 60 cases from the same sites for model benchmark testing, and additional 40 cases from the unseen site (breast and rectum) was used for model generalizability evaluation. The clinical calculated dose with a grid size of 2â¯mm was used as baseline dose distribution. The input included the dose distribution with 4â¯mm grid size and CT images. The model performance was compared with HD U-Net and cubic interpolation methods using Dose-volume histograms (DVH) metrics and global gamma analysis with 1%/1â¯mm and 10% low dose threshold. The correlation between the prediction error and the dose, dose gradient, and CT values was also evaluated. RESULTS: The prediction errors of MDSR were 0.06-0.84% of Dmean indices, and the gamma passing rate was 83.1-91.0% on the benchmark testing dataset, and 0.02-1.03% and 71.3-90.3% for the generalization dataset respectively. The model performance was significantly higher than the HD U-Net and interpolation methods (pâ¯<â¯0.05). The mean errors of the MDSR model decreased (monotonously by 0.03-0.004%) with dose and increased (by 0.01-0.73%) with the dose gradient. There was no correlation between prediction errors and the CT values. CONCLUSION: The proposed MDSR model achieved good agreement with the baseline high-resolution dose distribution, with small prediction errors for DVH indices and high gamma passing rate for both seen and unseen sites, indicating a robust and generalizable dose prediction model. The model can provide fast and accurate high-resolution dose distribution for clinical dose calculation, particularly for the routine practice of OLART.
RESUMO
Background: T1-2 breast cancer patients with only one sentinel lymph node (SLN) metastasis have an extremely low non-SLN (NSLN) metastatic rate and are favorable for axillary lymph node dissection (ALND) exemption. This study aimed to construct a nomogram-based preoperative prediction model of NSLN metastasis for such patients, thereby assisting in preoperatively selecting proper surgical procedures. Methods: A total of 729 T1-2 breast cancer patients with only one SLN metastasis undergoing sentinel lymph node biopsy and ALND were retrospectively selected from Harbin Medical University Cancer Hospital between January 2013 and December 2020, followed by random assignment into training (n=467) and validation cohorts (n=262). A nomogram-based prediction model for NSLN metastasis risk was constructed by incorporating the independent predictors of NSLN metastasis identified from multivariate logistic regression analysis in the training cohort. The performance of the nomogram was evaluated by the calibration curve and the receiver operating characteristic (ROC) curve. Finally, decision curve analysis (DCA) was used to determine the clinical utility of the nomogram. Results: Overall, 160 (21.9%) patients had NSLN metastases. Multivariate analysis in the training cohort revealed that the number of negative SLNs (OR: 0.98), location of primary tumor (OR: 2.34), tumor size (OR: 3.15), and lymph-vascular invasion (OR: 1.61) were independent predictors of NSLN metastasis. The incorporation of four independent predictors into a nomogram-based preoperative estimation of NSLN metastasis demonstrated a satisfactory discriminative capacity, with a C-index and area under the ROC curve of 0.740 and 0.689 in the training and validation cohorts, respectively. The calibration curve showed good agreement between actual and predicted NSLN metastasis risks. Finally, DCA revealed the clinical utility of the nomogram. Conclusion: The nomogram showed a satisfactory discriminative capacity of NSLN metastasis risk in T1-2 breast cancer patients with only one SLN metastasis, and it could be used to preoperatively estimate NSLN metastasis risk, thereby facilitating in precise clinical decision-making on the selective exemption of ALND in such patients.